Mr. Chris Dallin reports

ASEP MEDICAL ANNOUNCES CEASE TRADE ORDER

On May 5, 2026, Asep Medical Holdings Inc.'s principal regulator, the British Columbia Securities Commission (BCSC), issued a failure-to-file cease trade order (FFCTO), in accordance with Multilateral Instrument 11-103, Failure-to-File Cease Trade Orders in Multiple Jurisdictions. As a result of the FFCTO, the Canadian Securities Exchange has suspended trading in the company's securities.

The FFCTO was issued because of the company's delay in filing its audited annual financial statements and accompanying management's discussion and analysis for the fiscal year ended Dec. 31, 2025, which were due on April 30, 2026, in accordance with Canadian securities laws.

The company regrets this delay in filing and the inconvenience to shareholders. Asep management is working with its auditor to complete the annual filings as soon as possible. The FFCTO will remain in place until such time as the annual filings and all continuous disclosure requirements have been filed and the company receives an order from the BCSC revoking the FFCTO. The company will make further announcements with respect to the status of the annual filings and the FFCTO as and when appropriate.

The company continues to operate normally and does not expect any interruption to its operations during the FFCTO.

About Asep Medical Holdings Inc.

Asep Medical is a standout biotechnology research and development company based in Victoria, B.C., Canada. The company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E.W. Hancock, one of the world's foremost microbiologists. Asep holds a controlling interest in two private subsidiary companies -- Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors.

We seek Safe Harbor.